Yoshida Y, Kato H, Ikeda Y, Nangaku M (2019) Pathogenesis of atypical hemolytic uremic syndrome. J Atheroscler Thromb 26:99–110

Article  CAS  PubMed  PubMed Central  Google Scholar 

Yenerel MN (2019) Atypical hemolytic uremic syndrome: differential diagnosis from TTP/HUS and management. Atipik Hemolitik Üremik Sendrom: Ttp/Hüs ile Ayırıcı Tanısı ve Tedavisi. Turk J Haematol 31:216–225

Google Scholar 

Nester CM, Barbour T, de Cordoba SR, Dragon-Durey MA, Fremeaux-Bacchi V, Goodship TH, Kavanagh D, Noris M, Pickering M, Sanchez-Corral P, Skerka C, Zipfel P, Smith RJ (2015) Atypical aHUS: state of the art. Mol Immunol 67:31–42

Article  CAS  PubMed  Google Scholar 

Yerigeri K, Kadatane S, Mongan K, Boyer O, Burke LLG, Sethi SK, Licht C, Raina R (2023) Atypical hemolytic-uremic syndrome: genetic basis, clinical manifestations, and a multidisciplinary approach to management. J Multidiscip Healthc 16:2233–2249

Article  PubMed  PubMed Central  Google Scholar 

Jamme M, Raimbourg Q, Chauveau D, Seguin A, Presne C, Perez P, Gobert P, Wynckel A, Provôt F, Delmas Y, Mousson C, Servais A, Vrigneaud L, Veyradier A, Rondeau E, Coppo P, French Thrombotic Microangiopathies Reference Centre (2017) Predictive features of chronic kidney disease in atypical haemolytic uremic syndrome. PLoS ONE 12:e0177894

Article  PubMed  PubMed Central  Google Scholar 

Legendre CM, Licht C, Muus P, Greenbaum LA, Babu S, Bedrosian C, Bingham C, Cohen DJ, Delmas Y, Douglas K, Eitner F, Feldkamp T, Fouque D, Furman RR, Gaber O, Herthelius M, Hourmant M, Karpman D, Lebranchu Y, Mariat C, Menne J, Moulin B, Nürnberger J, Ogawa M, Remuzzi G, Richard T, Sberro-Soussan R, Severino B, Sheerin NS, Trivelli A, Zimmerhackl LB, Goodship T, Loirat C (2013) Terminal complement inhibitor eculizumab in atypical haemolytic-uremic syndrome. N Engl J Med 368:2169–2181

Article  CAS  PubMed  Google Scholar 

Rondeau E, Scully M, Ariceta G, Barbour T, Cataland S, Heyne N, Miyakawa Y, Ortiz S, Swenson E, Vallee M, Yoon SS, Kavanagh D, Haller H, 311 Study Group (2020) The long-acting C5 inhibitor, ravulizumab, is effective and safe in adult patients with atypical hemolytic uremic syndrome naïve to complement inhibitor treatment. Kidney Int 97:1287–1296

Article  CAS  PubMed  Google Scholar 

Ariceta G, Dixon BP, Kim SH, Kapur G, Mauch T, Ortiz S, Vallee M, Denker AE, Kang HG, Greenbaum LA, 312 Study Group (2021) The long-acting C5 inhibitor, ravulizumab, is effective and safe in pediatric patients with atypical hemolytic uremic syndrome naive to complement inhibitor treatment. Kidney Int 100:225–237

Article  CAS  PubMed  Google Scholar 

Licht C, Greenbaum LA, Muus P, Babu S, Bedrosian CL, Cohen DJ, Delmas Y, Douglas K, Furman RR, Gaber OA, Goodship T, Herthelius M, Hourmant M, Legendre CM, Remuzzi G, Sheerin N, Trivelli A, Loirat C (2015) Efficacy and safety of eculizumab in atypical hemolytic uremic syndrome from 2-year extensions of phase 2 studies. Kidney Int 87:1061–1073

Article  CAS  PubMed  PubMed Central  Google Scholar 

Greenbaum LA, Fila M, Ardissino G (2016) Eculizumab is a safe and effective treatment in pediatric patients with atypical hemolytic uremic syndrome. Kidney Int 89:701–711

Article  CAS  PubMed  Google Scholar 

Fakhouri F, Hourmant M, Campistol JM, Cataland SR, Espinosa M, Gaber AO, Menne J, Minetti EE, Provôt F, Rondeau E, Ruggenenti P, Weekers LE, Ogawa M, Bedrosian CL, Legendre CM (2016) Terminal complement inhibitor eculizumab in adult patients with atypical hemolytic uremic syndrome: a single-arm, open-label trial. Am J Kidney Dis 68:84–93

Article  CAS  PubMed  Google Scholar 

Brocklebank V, Walsh PR, Smith-Jackson K, Hallam TM, Marchbank KJ, Wilson V, Bigirumurame T, Dutt T, Montgomery EK, Malina M, Wong EKS, Johnson S, Sheerin NS, Kavanagh D (2023) Atypical hemolytic uremic syndrome in the era of terminal complement inhibition: an observational cohort study. Blood 142:1371–1386

Article  CAS  PubMed  PubMed Central  Google Scholar 

Emirova K, Volokhina E, Tolstova E, van den Heuvel B (2016) Recovery of renal function after long-term dialysis and resolution of cardiomyopathy in a patient with aHUS receiving eculizumab. BMJ Case Rep 2016:bcr2015213928

Article  PubMed  PubMed Central  Google Scholar 

Barbour T, Scully M, Ariceta G, Cataland S, Garlo K, Heyne N, Luque Y, Menne J, Miyakawa Y, Yoon SS, Kavanagh D, 311 Study Group Members (2021) Long-term efficacy and safety of the long-acting complement C5 inhibitor ravulizumab for the treatment of atypical hemolytic uremic syndrome in adults. Kidney Int Rep 6:1603–1613

Article  PubMed  PubMed Central  Google Scholar 

Walle JV, Delmas Y, Ardissino G, Wang J, Kincaid JF, Haller H (2017) Improved renal recovery in patients with atypical hemolytic uremic syndrome following rapid initiation of eculizumab treatment. J Nephrol 30:127–134

Article  PubMed  Google Scholar 

Maruyama S, Ikeda Y, Kaname S, Kato N, Matsumoto M, Ishikawa Y, Shimono A, Miyakawa Y, Nangaku M, Shibagaki Y, Okada H (2024) Eculizumab for adult patients with atypical haemolytic-uremic syndrome: full dataset analysis of Japanese post-marketing surveillance. J Nephrol 37:2181–2190

Article  CAS  PubMed  PubMed Central  Google Scholar 

Ito S, Hidaka Y, Inoue N, Kaname S, Kato H, Matsumoto M, Miyakawa Y, Mizuno M, Okada H, Shimono A, Matsuda T, Maruyama S, Fujimura Y, Nangaku M, Kagami S (2019) Safety and effectiveness of eculizumab for pediatric patients with atypical hemolytic-uremic syndrome in Japan: interim analysis of post-marketing surveillance. Clin Exp Nephrol 23:112–121

Article  CAS  PubMed  Google Scholar 

Ito S, Hataya H, Ashida A, Hamada R, Ishikawa T, Ishikawa Y, Shimono A, Konomoto T, Miyazawa T, Ogura M, Tanaka K, Kagami S (2023) Eculizumab for paediatric patients with atypical haemolytic uraemic syndrome: full dataset analysis of post-marketing surveillance in Japan. Nephrol Dial Transplant 38:414–424

Article  CAS  PubMed  Google Scholar 

Kato H, Miyakawa Y, Hidaka Y, Inoue N, Ito S, Kagami S, Kaname S, Matsumoto M, Mizuno M, Matsuda T, Shimono A, Maruyama S, Fujimura Y, Nangaku M, Okada H (2019) Safety and effectiveness of eculizumab for adult patients with atypical hemolytic-uremic syndrome in Japan: interim analysis of post-marketing surveillance. Clin Exp Nephrol 23:65–75

Article  CAS  PubMed  Google Scholar 

Sawai T, Nangaku M, Ashida A, Fujimaru R, Hataya H, Hidaka Y, Kaname S, Okada H, Sato W, Yasuda T, Yoshida Y, Fujimura Y, Hattori M, Kagami S, Joint Committee of the Japanese Society of Nephrology and the Japan Pediatric Society (2014) Diagnostic criteria for atypical hemolytic uremic syndrome proposed by the Joint Committee of the Japanese Society of Nephrology and the Japan Pediatric Society. Clin Exp Nephrol 18:4–9

Article  CAS  PubMed  Google Scholar 

Kato H, Nangaku M, Hataya H, Sawai T, Ashida A, Fujimaru R, Hidaka Y, Kaname S, Maruyama S, Yasuda T, Yoshida Y, Ito S, Hattori M, Miyakawa Y, Fujimura Y, Okada H, Kagami S, Joint Committee for the Revision of Clinical Guides of Atypical Hemolytic Uremic Syndrome in Japan (2016) Clinical guides for atypical hemolytic uremic syndrome in Japan. Clin Exp Nephrol 20:536–543

Article  CAS  PubMed  Google Scholar 

Kato H, Nangaku M, Okada H, Kagami S (2018) Controversies of the classification of TMA and the terminology of aHUS. Clin Exp Nephrol 22:979–980

Article  PubMed  Google Scholar 

Tatematsu Y, Imaizumi T, Michihata N, Kato N, Kumazawa R, Matsui H, Fushimi K, Yasunaga H, Maruyama S (2024) Annual trends in atypical haemolytic uremic syndrome management in Japan and factors influencing early diagnosis and treatment: a retrospective study. Sci Rep 14:18265

Article  CAS  PubMed  PubMed Central  Google Scholar 

Dixon BP, Kavanagh D, Aris ADM, Adams B, Kang HG, Wang E, Garlo K, Ogawa M, Amancha P, Chakravarty S, Heyne N, Kim SH, Cataland S, Yoon SS, Miyakawa Y, Luque Y, Muff-Luett M, Tanaka K, Greenbaum LA (2024) Ravulizumab in atypical hemolytic uremic syndrome: an analysis of 2-year efficacy and safety outcomes in 2 phase 3 trials. Kidney Med 6:100855

Article  PubMed  PubMed Central  Google Scholar 

Goodship TH, Cook HT, Fakhouri F, Fervenza FC, Frémeaux-Bacchi V, Kavanagh D, Nester CM, Noris M, Pickering MC, Rodríguez de Córdoba S, Roumenina LT, Sethi S, Smith RJ, Participants C (2017) Atypical hemolytic uremic syndrome and C3 glomerulopathy: conclusions from a “Kidney Disease: Improving Global Outcomes” (KDIGO) Controversies Conference. Kidney Int 91:539–551

Article  CAS  PubMed  Google Scholar 

Ávila A, Cao M, Espinosa M, Manrique J, Morales E (2023) Recommendations for the individualised management of atypical hemolytic uremic syndrome in adults. Front Med (Lausanne) 10:1264310

Article  PubMed  Google Scholar 

Daugirdas JT, Bernardo AA (2012) Hemodialysis effect on platelet count and function and hemodialysis-associated thrombocytopenia. Kidney Int 82:147–157

Article  CAS  PubMed  Google Scholar